Skip to main content
. 2019 May 9;20(1):135–140. doi: 10.3892/mmr.2019.10224

Figure 1.

Figure 1.

(A) SK-ES-1 cells and RD-ES cells were treated with different concentrations of toosendanin (0, 1, 2, 5, 10, 20, 40, 50 and 60 µM) for 24 h and a CCK-8 assay was performed to detect cell viability after treatment. Data are expressed as the mean ± SD of three independent experiments. *P<0.05, **P<0.01 and ***P<0.001 vs. the control. (B) SK-ES-1 cells were treated with different concentrations of toosendanin (0, 1, 2, 5, 10, 20, 40, 50 and 60 µM) for 24, 36, and 48 h and then a CCK-8 assay was performed to detect cell viability after treatment. Data are expressed as the mean ± SD of three independent experiments. ***P<0.001 vs. the control.